



SciTech Development, LLC

FOR IMMEDIATE RELEASE

Private Equity Firm Invests in SciTech

(GROSSE POINTE FARMS, MI) August 20, 2019 – SciTech Development is pleased to announce that Nano Investments, LLC, a private equity firm from Rochester, Michigan has made a significant investment in SciTech via its Convertible Note Round (CNR) of funding. SciTech will use the funds for the scale-up, preparation and initiation of a Phase 1 clinical trial of ST-001 for the treatment of T-cell non-Hodgkin's lymphoma (NHL). SciTech is currently seeking a Series A equity raise of approximately \$15MM to bring its lead product ST-001 to market for the treatment of NHL and small cell lung cancer (SCLC).

SciTech's lead compound ST-001 nanoFenretinide is a small-molecule cancer drug employing a nanoparticle suspension for intravenous administration. ST-001 nanoFenretinide is comprised of fenretinide in a patented combination with carefully selected non-toxic phospholipids. SciTech's product pipeline includes treatment for several other cancer indications.

The company has submitted an Investigational New Drug (IND) Application for ST-001 in the treatment of NHL. The FDA has already granted Orphan Drug Status for ST-001 in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

Information regarding SciTech's nano formulation technology and oncology drug product ST-001 nanoFenretinide is available from SciTech Development, LLC by calling (313) 938-5517 or online at <https://www.scitechdevelopment.com/>.

About SciTech Development

SciTech Development, LLC is a clinical stage, pharmaceutical company that has developed unique nano-delivery systems (SciTech Delivery Vehicle-SDV) to enable intravenous (IV) delivery of water-insoluble drugs. One such challenged drug is fenretinide which has been shown in extensive clinical trials to be a safe and effective anticancer therapy with targeted cancer

destroying activity. The combination of the new SDV and fenretinide has led to SciTech’s first drug product, ST-001 nanoFenretinide, which holds the promise of improving and saving many lives. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. More information regarding SciTech’s nano-delivery technology and oncology drug product ST-001 is available at <https://www.scitechdevelopment.com/>

Selected Product Pipeline

- ST-001 – Intravenous fenretinide formulation for the treatment of NHL.
- ST-002 – Topical formulation for the treatment of various skin cancers and bed sores.
- ST-003 – Intravenous formulation for the treatment of small cell lung cancer (SCLC).
- ST-004 – Intravenous formulation for the treatment of metastatic breast cancer (MBC).
- ST-005 – Intravenous formulation for the treatment of neuroblastoma (pediatric cancer).
- ST-006 – Intravenous formulation for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).

For More Information: Earle T. Holsapple, President
SciTech Development, LLC
(313) 938-5517

Forward-Looking Information

This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC (“the Company”), future expectations, plans and prospects. In particular, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.



###